Where FDA breakthrough devices stand through 2025: growth, authorizations, leading specialties, AI trends, and qualification pathways explained.
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...
Sentante announced that its Sentante stroke system has been accepted into the FDA Total Product Life Cycle Advisory Program ...
4d
Dr. Dayan Goodenowe Announces FDA Clinical Development Program for a Novel Alzheimer’s Therapeutic
Extensive peer-reviewed research has identified biologically active nutrients and biochemical intermediates that play ...
The U.S. Food and Drug Administration headquarters in Silver Spring, Md., on Nov. 10, 2020. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our ...
MacroGenics (MGNX) fell ~18% in the premarket on Tuesday after the cancer drug developer announced that the U.S. FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results